Icon Plc (ICLR) Earns Daily News Sentiment Score of 0.18
Press coverage about Icon Plc (NASDAQ:ICLR) has been trending somewhat positive this week, Accern Sentiment reports. The research firm identifies negative and positive press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Icon Plc earned a news sentiment score of 0.18 on Accern’s scale. Accern also assigned press coverage about the medical research company an impact score of 46.0375704418429 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Here are some of the news stories that may have effected Accern Sentiment Analysis’s analysis:
- Zacks Investment Research Upgrades Icon Plc (ICLR) to Buy (americanbankingnews.com)
- ICON PLC (ICLR) Expected to Post Quarterly Sales of $439.45 Million (americanbankingnews.com)
- Short Interest in Icon Plc (ICLR) Grows By 30.4% (americanbankingnews.com)
- Icon Plc (ICLR) Lowered to “Hold” at Zacks Investment Research (americanbankingnews.com)
- $1.32 EPS Expected for Icon Plc (ICLR) This Quarter (americanbankingnews.com)
Shares of Icon Plc (ICLR) opened at 112.47 on Wednesday. The firm has a 50 day moving average price of $108.70 and a 200 day moving average price of $93.99. Icon Plc has a 12-month low of $73.76 and a 12-month high of $117.53. The stock has a market cap of $6.08 billion, a PE ratio of 22.81 and a beta of 0.61.
Icon Plc (NASDAQ:ICLR) last released its quarterly earnings data on Thursday, July 27th. The medical research company reported $1.31 earnings per share for the quarter, topping analysts’ consensus estimates of $1.30 by $0.01. The firm had revenue of $431.00 million during the quarter, compared to analyst estimates of $430.68 million. Icon Plc had a return on equity of 28.72% and a net margin of 15.97%. The business’s quarterly revenue was up 5.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.14 earnings per share. On average, equities analysts expect that Icon Plc will post $5.32 EPS for the current year.
ICLR has been the topic of a number of recent research reports. Jefferies Group LLC raised Icon Plc from a “hold” rating to a “buy” rating and increased their price objective for the stock from $86.00 to $117.00 in a report on Thursday, June 29th. Goldman Sachs Group, Inc. (The) raised Icon Plc from a “buy” rating to a “conviction-buy” rating and set a $117.00 price objective on the stock in a report on Friday, July 7th. Credit Suisse Group reissued an “outperform” rating and set a $102.00 price objective (up previously from $91.00) on shares of Icon Plc in a report on Tuesday, June 6th. Zacks Investment Research raised Icon Plc from a “hold” rating to a “buy” rating and set a $108.00 price objective on the stock in a report on Tuesday, June 27th. Finally, BidaskClub raised Icon Plc from a “hold” rating to a “buy” rating in a report on Friday, June 23rd. Two investment analysts have rated the stock with a hold rating, nine have assigned a buy rating and two have given a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $113.00.
About Icon Plc
ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.
Receive News & Stock Ratings for Icon Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon Plc and related stocks with our FREE daily email newsletter.